<DOC>
	<DOCNO>NCT02265913</DOCNO>
	<brief_summary>To compare safety efficacy Perrigo 's antiviral drug product compare FDA approve antiviral drug product treatment cold sore .</brief_summary>
	<brief_title>Comparative Safety Efficacy Two Antiviral Treatments Treatment Recurrent Herpes Simplex Labialis</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>1 . Provides write informed consent/assent 2 . Immunocompetent male nonpregnant female , &gt; 12 year old , limited , nonlifethreatening , recurrent herpes simplex labialis . 3 . Subjects must least 3 recurrence herpes simplex labialis per year past two year . 4 . Females childbearing potential willing use acceptable form birth control . 5 . Subjects must general good health clinically significant disease might interfere study evaluation opinion investigator . 6 . Subjects must willing able understand comply requirement study . 1 . Females pregnant nursing , use agree use acceptable form contraception study , intend become pregnant study . 2 . The use antiviral therapy various form give period time prior screening study medication application . 3 . Candidate previous use parenteral antiviral treatment prophylactic antiviral therapy recurrent herpes simplex labialis . 4 . Recently receive organ transplant . 5 . Subjects immunocompromised , HIV positive immunesystem disorder . 6 . Recent major change immune system status could seriously affect clinical manifestation herpes simplex labialis need treatment opinion investigator . 7 . Subjects know suspected history clinically significant systemic disease , unstable medical disorder , lifethreatening disease current malignancy . 8 . Subjects current episode herpes simplex labialis completely heal . 9 . Presence facial skin condition excessive facial hair may interfere diagnosis , assessment , and/or heal ability . 10 . History herpes keratitis . 11 . Subject history hypersensitivity allergy ingredient drug product . 12 . History unresponsiveness topical acyclovir therapy . 13 . Participation clinical study receive treatment investigational drug device within 30 day prior screen . 14 . Subjects previously enrol study . 15 . Subjects receive local medication target area 2 week prior enrollment/screening Day 1 ( Visit 2 ) . 16 . Subjects treat immunosuppressive medication therapy within 8 week prior study enrollment/screening Day 1 ( Visit 2 ) . 17 . Subject consumes excessive alcohol , abuse drug , condition could compromise subject 's ability comply study requirement investigator 's opinion . 18 . Use tanning booth , sun lamp , excessive exposure sun 21 day initiate study medication 19 . Subjects use immunostimulators , dyelight therapy , psoralen therapy within 30 day prior study medication initiation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>